Neurokinin-1 Receptor Antagonists
"Neurokinin-1 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS.
| Descriptor ID |
D064729
|
| MeSH Number(s) |
D27.505.519.625.487 D27.505.696.577.487
|
| Concept/Terms |
Neurokinin-1 Receptor Antagonists- Neurokinin-1 Receptor Antagonists
- Antagonists, Neurokinin-1 Receptor
- Neurokinin 1 Receptor Antagonists
- Receptor Antagonists, Neurokinin-1
- Neuroleukin-1 Receptor Blockers
- Blockers, Neuroleukin-1 Receptor
- Neuroleukin 1 Receptor Blockers
- Receptor Blockers, Neuroleukin-1
- Substance P Receptor Antagonists
- Tachykinin Receptor 1 Antagonists
- Tachykinin Receptor 1 Blockers
- Neurokinin-1 Receptor Blockers
- Blockers, Neurokinin-1 Receptor
- Neurokinin 1 Receptor Blockers
- Receptor Blockers, Neurokinin-1
- Substance P Receptor Blockers
|
Below are MeSH descriptors whose meaning is more general than "Neurokinin-1 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Neurokinin-1 Receptor Antagonists".
This graph shows the total number of publications written about "Neurokinin-1 Receptor Antagonists" by people in this website by year, and whether "Neurokinin-1 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurokinin-1 Receptor Antagonists" by people in Profiles.
-
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant. Int J Mol Sci. 2023 Nov 03; 24(21).
-
Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy? Curr Med Chem. 2023; 30(16):1798-1812.
-
Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential. Mol Psychiatry. 2018 08; 23(8):1745-1755.
-
Substance P receptor antagonism: a potential novel treatment option for viral-myocarditis. Biomed Res Int. 2015; 2015:645153.
-
Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol. 2014 May 01; 306(9):G759-68.
-
Substance P causes seizures in neurocysticercosis. PLoS Pathog. 2012 Feb; 8(2):e1002489.
-
A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol. 2011 Mar; 21(3):221-9.
-
Substance P receptor antagonism for treatment of cryptosporidiosis in immunosuppressed mice. J Parasitol. 2008 Oct; 94(5):1150-4.
-
Substance P receptor antagonist reverses intestinal pathophysiological alterations occurring in a novel ex-vivo model of Cryptosporidium parvum infection of intestinal tissues derived from SIV-infected macaques. J Med Primatol. 2008 Jun; 37(3):109-15.
-
A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. 2007 May; 104(5):1082-9, tables of contents.